Clinical Trials Logo

MDS clinical trials

View clinical trials related to MDS.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04857645 Active, not recruiting - AML Clinical Trials

ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

Start date: June 22, 2021
Phase: Phase 2
Study type: Interventional

Study of early administration of ASTX727 associated with late Donor Lymphocyte Infusions after allogenic stem cell transplantation in very high risk MDS or AML patients

NCT ID: NCT04806906 Active, not recruiting - MDS Clinical Trials

Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients

FLO_CC-486-
Start date: March 24, 2021
Phase: Phase 2
Study type: Interventional

Treatment of higher-risk (intermediate, high and very high) Myelodysplastic Syndromes (MDS) according to the revised International Prognostic Scoring System (IPSS-R) who obtained a stable hematological response ( CR, PR) after subcutaneous azacitidine treatment. Azacitidine is administered in hospital in a day care regimen, in Italy only by subcutaneous injection. The long duration of therapy obliges patients to travel to the hospital regularly, with evident worsening quality of life, both for patients and caregivers, although balanced by prolongation of survival and hematological improvement. Many patients stop therapy or are reluctant to continue because of the dependence from caregivers and hospital care. This clinical study will evaluate the efficacy and safety of oral azacitidine (CC-486) plus best supportive care in subjects with higher-risk (intermediate, high and very high) Myelodysplastic Syndrome (MDS) according to the revised International Prognostic Scoring System (IPSS-R) and (high and INT-2) according to IPSS who obtained a stable hematological response (CR, PR, SD with HI) after at least 4-6 cycles of subcutaneous azacitidine treatment and maintained for 2 additional cycles.

NCT ID: NCT04749355 Active, not recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS

Start date: November 14, 2021
Phase: Phase 2
Study type: Interventional

An open label multi center study to assess the safety and efficacy of BST-236 as single agent in adult patients unfit for standard therapy with Acute Myeloid Leukemia (AML) or higher-risk (HR) Myelodysplastic Syndromes (MDS) who fail to respond or relapsed following first line therapy. Approximately 20 adult patients with relapsed and/or refractory AML and approximately 20 adult patients with relapsed and/or refractory HR MDS, will be enrolled into the study. Patients will be treated with 1-2 induction courses and 2-4 maintenance courses. All patients will be followed for 1 year in the study and additional 1 year post study follow-up.

NCT ID: NCT04623944 Active, not recruiting - MDS Clinical Trials

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Start date: September 21, 2020
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.

NCT ID: NCT04473911 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Haplo Peripheral Blood Sct In GVHD Prevention

Start date: August 14, 2020
Phase: Phase 1
Study type: Interventional

This research study is studying the RGI-2001 for preventing Graft-vs-Host Disease (GVHD) in people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative disorders (MPN), chronic myelomonocytic leukemic (CMML), chemosensitive hodgkin lymphoma (HL), or Non-Hodgkin lymphoma (NHL).who will have a blood stem cell transplantation. - GVHD is a condition in which cells from the donor's tissue attack the organs. - RGI-2001 is an investigational treatment

NCT ID: NCT03275636 Active, not recruiting - AML Clinical Trials

Haploidentical Donor vs mMUD in Hematological Malignancies

HAMLET
Start date: January 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this trial is to compare the outcome after partially matched (single mismatch) unrelated donor transplantation with haploidentical transplantation in a randomized controlled setting.

NCT ID: NCT02757989 Active, not recruiting - MDS Clinical Trials

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

Start date: May 31, 2016
Phase: N/A
Study type: Interventional

Comparison of survival in patients with or without a matched donor at 36 months

NCT ID: NCT01718366 Active, not recruiting - MDS Clinical Trials

A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS

GFM-EXVD-AZA
Start date: February 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Determinate safety and response rate of the association Deferasirox -Vitamine D - Azacitidine in treatment of high risk MDS Deferasirox Exjade: The dose of Deferasirox will be assigned according to the ferritin level. Dose escalation is scheduled during the phase I, with 5 additional patients per group. The maximal tolerated dose of Deferasirox will be required for the phase II of the study. The first dose will be assigned according to the ferritin level of the patient at time of inclusion: 5 mg/kg/d if the ferritin is >300ng/ml and < 1000ng/ml in Group 1 10 mg/kg/d if the ferritin is ≥1000ng/ml) in Group 2 Group 1 : Ferritin 300 to 1000ng /ml: - cohort 1 : 5 mg/kg/d - cohort 2 : 10mg/kg/d - cohort 3 : 15 mg/kg/d Group 2 : Ferritin > 1000ng /ml: - cohort 1 : 10 mg/kg/d - cohort 2 : 15mg/kg/d - cohort 3 : 20 mg/kg/d 5 patients will be treated by cohort. In absence of toxicity (extra-hematological toxicity grade 3 or 4 or hematological grade 4), 5 additional patients will be included in the next cohort. Deferasirox will be administrated once daily during all the study period. Uvedose will be administrated once weekly during all the study period (100.000 UI P.O). Azacitidine will be administrated sc at 75 mg/m²/d, during 7 days, J1 to J7 of each cycles(One cycle is 28 days) During phase I and II, Deferasirox will always be associated with Vitamin D and Azacitidine Patients will be received 6 cycles of treatment (except if progression, unacceptable toxicity or withdrawn of patients occured) After 3 and 6 cycles, an evaluation will be done to evaluate the efficacy of the treatment. No dose modification of deferasirox will be done after 3 cycles of treatment except in case of progression). After 6 cycles, patients with CR, PR, marrow CR or HI will be treated with the same dose of Deferasirox until progression .

NCT ID: NCT01342692 Active, not recruiting - MDS Clinical Trials

Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes

AZA-PLUS
Start date: June 2011
Phase: Phase 2
Study type: Interventional

In order to improve the overall survival benefit observed with AZA in higher risk MDS, its combination with other active drugs in MDS must be tested. Among drugs that have demonstrated to be active as a single agent in MDS and have preclinical potential additive or synergistic activity with AZA are Histone deacetylase (HDAC) inhibitors including Valproic acid, Lenalidomide and idarubicin. Phase I studies have already been conducted or are being conducted combining those agents to demethylating agents, showing a low toxicity profile and significant responses in high risk MDS. In this phase II randomized trial, we want to identify the most promising combination of Azacitidine and another drug (among 3 drugs: Valproic acid, Lenalidomide and Idarubicin) in higher risk MDS, by comparison to Azacitidine alone. Of note, based on efficacy and toxicity, one or several combinations may be stopped, and others, previously tested in phase I trials, included after protocol amendment.